Provided by Tiger Trade Technology Pte. Ltd.

Nektar Therapeutics

71.62
-2.4050-3.25%
Volume:89.34K
Turnover:6.42M
Market Cap:2.45B
PE:-11.07
High:73.95
Open:73.01
Low:70.93
Close:74.02
52wk High:109.00
52wk Low:26.45
Shares:34.14M
Float Shares:28.53M
Volume Ratio:1.44
T/O Rate:0.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.4680
EPS(LYR):-9.7254
ROE:-35.75%
ROA:-12.54%
PB:2.71
PE(LYR):-7.36

Loading ...

Nektar Therapeutics Announces Press Release on Start of Phase 3 Zenith AD Program for Rezpegaldesleukin in Atopic Dermatitis

Reuters
·
Jul 21

Nektar Therapeutics - Zenith Ad Program to Enroll 1,530 Patients Across Three Phase 3 Studies

THOMSON REUTERS
·
Jul 21

Nektar Therapeutics Announces Start of Phase 3 Zenith Ad Program Evaluating Novel Regulatory T-cell Biologic Rezpegaldesleukin in Moderate-to-severe Atopic Dermatitis

THOMSON REUTERS
·
Jul 21

Nektar Therapeutics - Initial Phase 3 Topline Data Expected Mid-2028; Bla Submission Targeted for 2029

THOMSON REUTERS
·
Jul 21

Nektar Therapeutics (NKTR) Stock Looks Above Fair Value Despite Its 7x Run

Simply Wall St.
·
Jul 20

Nektar’s Phase 3 Eczema Bet: What Rezpegaldesleukin Could Mean for NKTR Stock

TIPRANKS
·
Jul 18

Nektar Therapeutics (NKTR) Advances Autoimmune Pipeline, Is The Upside Already Priced In?

Simply Wall St.
·
Jul 06

Nektar Therapeutics Chief R&D Officer Jonathan Zalevsky Sells 5,681 Shares for $397,670

Reuters
·
Jul 03

Nektar Grants New Hires Options for 20,500 Shares at $60.98 Each Under Inducement Plan

Reuters
·
Jun 27

Nektar Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jun 27

Nektar Therapeutics CEO Robin Howard sells USD 1.2 million in common shares

Reuters
·
Jun 19

Nektar Chief R&D Officer Jonathan Zalevsky sells 5,538 shares for $336,412.98

Reuters
·
Jun 18

Nektar grants inducement stock options for 11,900 shares at $69.49 each

Reuters
·
Jun 04

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 04

Nektar Therapeutics to present at Jefferies Global Healthcare Conference via webcast

Reuters
·
May 28

Nektar Therapeutics interim CFO Linda M. Rubinstein files initial beneficial ownership statement

Reuters
·
May 27

Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), BeOne Medicines (ONC) and Nektar Therapeutics (NKTR)

TIPRANKS
·
May 14

Assessing Nektar Therapeutics (NKTR) Valuation After Its Recent Share Price Recovery

Simply Wall St.
·
May 13

Nektar price target lowered to $80 from $95 at Wedbush

TIPRANKS
·
May 12

Stock Track | Nektar Therapeutics Plummets 5.13% Intraday After Wedbush Cuts Price Target

Stock Track
·
May 11